Vasculitis

Session Type: ACR Abstract Submissions
Tuesday, November 8, 2011: 9:00 AM-6:00 PM
Hall F2 - Poster Hall (McCormick Place West)
Papers:
CTLA-4 and TNF-á Promoter –308 A/G Polymorphisms and ANCA-Associated Vasculitis Susceptibility: A Meta-Analysis
Young Ho Lee, Sung Jae Choi, Jong Dae Ji and Gwan Gyu Song, Korea University Medical Center, Seoul, South Korea
How Do Rheumatologists Choose Between Cyclophosphamide and Rituximab?
Raluca Cozmuta, St. Vincent Medical Center, Bridgeport, CT, Peter A. Merkel, Boston University School of Medicine, Boston, MA and Liana Fraenkel, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT
Treatment for ANCA-Associated Vasculitis: What Are the Experts Prescribing?
Raluca Cozmuta, St. Vincent Medical Center, Bridgeport, CT, Peter A. Merkel, Boston University School of Medicine, Boston, MA and Liana Fraenkel, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT
Are Patients with ANCA-Associated Vasculitis Entered In Clinical Trials Representative of Patients Followed In Observational Cohorts?
Christian Pagnoux1, Simon Carette2, Nader A. Khalidi3, David Cuthberston4, Paul R. Fortin5, Gary S. Hoffman6, Carol A. Langford7, Paul A. Monach8, Luc Mouthon9, Philip Seo10, Ulrich Specks11, Steven R. Ytterberg11, Peter A. Merkel12, Loic Guillevin13, French Vasculitis Study Group (FVSG)14 and The Vcrc8, 1University Health Network, Toronto, Canada, Toronto, ON, 2Toronto Western Hospital, Toronto, ON, 3McMaster University, Hamilton, ON, 4University of South Florida, Tampa, FL, 5Toronto Western Hospital and University of Toronto, Toronto, ON, 6Cleveland Clinic Found A50, Cleveland, OH, 7Cleveland Clinic, Cleveland, OH, 8Boston University, Boston, MA, 9Hopital Cochim, Paris, France, 10Johns Hopkins Vasculitis Center, Baltimore, MD, 11Mayo Clinic, Rochester, MN, 12Boston University School of Medicine, Boston, MA, 13Cochin University Hospital, Paris, France, 14Paris, France
Optimal Definition for the Duration of Sustained Remission in ANCA-Associated Vasculitis
Gunnar Tomasson1, Michael Walsh2, Thomas F. Hiemstra3, Maarten Boers4, Peter A. Merkel1 and EUVAS Investigators5, 1Boston University School of Medicine, Boston, MA, 2McMaster University, Hamilton, 3Addenbrookexs Hospital University of Cambridge, Cambridge, United Kingdom, 4VU University Medical Center, Amsterdam, Netherlands, 5Cambridge, United Kingdom
Neural Correlates of Chronic Fatigue in Granulomatosis with Polyangiitis (GPA; Wegener’s) – A Functional Magnetic Resonance Imaging (fMRI) Study
Neil Basu1, Gareth T. Jones1, Raashid A. Luqmani2, Alison D. Murray1, David M. Reid1, Gary J. Macfarlane1 and Gordon D. Waiter1, 1University of Aberdeen, Aberdeen, United Kingdom, 2University of Oxford, Oxford, United Kingdom
Mental Health As a Predictor of Disease Flare in Granulomatosis with Polyangiitis (Wegener's Granulomatosis)
Morgana L. Davids1, Huong Do1, Gunnar Tomasson2, John C. Davis3, Gary S. Hoffman4, W. Joseph McCune5, Ulrich Specks6, E. William St Clair7, John H. Stone8, Peter A. Merkel9 and Robert F. Spiera1, 1Hospital for Special Surgery, New York, NY, 2Boston University School of Medicine, Boston, MA, 3Genentech Inc, South San Francisco, CA, 4Cleveland Clinic, Cleveland, OH, 5University of Michigan, Ann Arbor, MI, 6Mayo Clinic, Rochester, MN, 7Duke University Medical Center, Durham, NC, 8Massachusetts General Hospital, Boston, MA, 9Boston University, Boston, MA
Patient-Driven On-Line Survey on Granulomatosis with Polyangiitis
Adam Hall1, Marta Rode2, Christian Pagnoux3 and Elaine Yacyshyn1, 1University of Alberta, Edmonton, AB, 2None, Jasper, AB, 3University of Toronto, Toronto, ON
Rituximab in Relapsing Granulomatosis with Polyangiitis (Wegener's granulomatosis): a Case Series
Pamela M.K Lutalo, Ian C. Scott, Shirish Sangle and David P. D'Cruz, Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom
B Cell Depletion by Rituximab Severely Reduces Immunoglobulin Levels in Patients with ANCA-Associated Vasculitis Previously Treated with Cyclophosphamide
Jens Thiel, Nora M. Effelsberg, Hans-Hartmut Peter, Reinhard E. Voll, Klaus Warnatz and Nils Venhoff, Dpt. Rheumatology and Centre for Chronic Immunodeficiency, University Hospital Freiburg, Freiburg, Germany
A Cost Effectiveness Analysis of Weekly Complete Blood Count Monitoring for Leukopenia In Patients with Granulomatosis with Polyangiitis (Wegner's) On Cyclophosphamide
Atul A. Khasnis1, Richard Wilson2, Gary S. Hoffman1, Alexandra Villa-Forte1 and Carol A. Langford3, 1Cleveland Clinic Foundation, Cleveland, OH, 2Case Western Reserve University, Cleveland, OH, 3Cleveland Clinic, Cleveland, OH
Perspective on Hypoxic Signalling in Granulomatosis with Polyangiitis (Wegener’s) – Increased Expression of HIF-1α and Glut-1 in Granulomatous Lesions of the Nasal Cavity
Nina Kesel1, Antje Müller2, Dorothee Köhler1, Martin Laudien3, Elena Csernok2, Udo Schumacher1 and Sebastian Ullrich1, 1University Medical Center Hamburg, Hamburg, Germany, 2University of Lübeck, Bad Bramstedt, Germany, 3Christian-Albrechts-University Kiel, Kiel, Germany
CT Imaging Characteristics of the Sino-Nasal Tract and Orbits in granulomatosis with Polyangiitis (Wegener’s) and Churg–Strauss Syndrome. A Cross-Sectional Review
Khaldoun Chaabo1, Shirish Sangle2, Dhiren Shah3, Hema Verma4 and David P. D'Cruz2, 1St Thomas' Hospital, London, SE1 7EH, United Kingdom, 2Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom, 3Guy's and St Thomas' Hospitals NHS Foundation Trust, London,SE1 9RT, United Kingdom, 4Guy's and St Thomas' Hospitals NHS Foundation Trust, London, SE1 9RT, United Kingdom
Churg–Strauss Syndrome: Analysis of 58 patients’ Relapses and Outcomes
Maxime Samson, Hôpital Cochin, University Paris Descartes, Paris, France, Camillo Ribi, Hôpital Universitaire Cantonal de Genève, Geneve, Switzerland, Pascal Cohen, Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, 75005 Paris, France., Paris, France, Marc Stern, Hôpital Foch, Suresnes, France, Christian Pagnoux, University of Toronto, Toronto, ON, Jean-Francois Cordier, Division of Pneumology, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon 1, Lyon, France, Luc Mouthon, Hopital Cochim, Paris, France and Loic Guillevin, Cochin University Hospital, Paris, France
IgG4 Immune Response in Churg-Strauss Syndrome
Augusto Vaglio1, Johanna Strehl2, Bernhard Manger2, Federica Maritati1, Federico Alberici1, Christian Beyer2, Juergen Rech2, Jorg HW Distler2, Georg Schett2, Renato Sinico3 and Jochen Zwerina2, 1University of Parma, Parma, Italy, 2University of Erlangen-Nuremberg, Erlangen, Germany, 3Ospedale San Carlo Borromeo, Milano, Italy
Airway Inflammation and Systemic Inflammation During Churg-Strauss Syndrome Natural Course: A Multidisciplinary Monocentric Crosse-Sectional Study
Chiara Baldini1, Sara Grossi1, Manuela Latorre2, Pasquale Pepe1, Valeria Giorgerini1, Alessandra Della Rossa1, Federico Dente2, Silvia Cianchetti2, Pierluigi Paggiaro2 and Stefano Bombardieri1, 1Rheumatology Unit, Pisa, Italy, 2Pneumology Unit, Italy
Cell Clonality in Churg-Strauss Syndrome: What Pathogenetic Role?
Chiara Baldini1, Sara Galimberti2, Pasquale Pepe1, Sara Grossi1, Elisabetta Sordi2, Valeria Giorgerini1, Alessandra Della Rossa1 and Stefano Bombardieri1, 1Rheumatology Unit, Pisa, Italy, 2Hematology Unit, Pisa, Italy
Cocaine and ANCA Associated Vasculitis-Like Syndromes: A Single Centre Study
Khaldoun Chaabo, St Thomas' Hospital, London, SE1 7EH, United Kingdom, Shirish Sangle, Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom and David P. D'Cruz, St Thomas' Hospital, London, United Kingdom
Rituximab Therapy for Systemic Vasculitis Associated with Rheumatoid Arthritis in the AutoImmunity and Rituximab Registry
Xavier Puéchal1, Jacques-Eric Gottenberg2, Jean-Marie Berthelot3, Laure Gossec4, Olivier Meyer5, Jacques Morel6, Daniel Wendling7, Michel De Bandt8, Eric Houvenagel9, Bénédicte Jamard10, Thierry Lequerré11, Gauthier Morel12, Pascal Richette13, Jérémie Sellam14, Loic Guillevin4 and Xavier Mariette for the AutoImmunity and Rituximab Registry15, 1Center for Rare Systemic Auto-immune Diseases, Le Mans General Hospital, Le Mans, France, 2Strasbourg University Hospital, Strasbourg, France, 3Nantes University Hospital, Nantes, France, 4Cochin University Hospital, Paris, France, 5Bichat University Hospital, Paris, France, 6Montpellier University Hospital, Montpellier, France, 7Minjoz University Hospital, Besancon, France, 8R. Ballanger Hospital, Aulnay Sous Bois, France, 9St Philibert Hospital, Lomme, France, 10Toulouse University Hospital, Toulouse, France, 11Rouen University Hospital, Rouen, France, 12Valenciennes Hospital, Valenciennes, France, 13Lariboisière University Hospital, Paris, France, 14St Antoine University Hospital, Paris, France, 15Bicêtre University Hospital, Le Kremlin Bicetre, France
Assessment of Disease Activity in Behcet Disease: Comparison of Behcet's Disease Current Activity Form (bdcaf), Behcet’s Syndrome Activity Score (bsas) and Routine Assessment of Patient Index Data (rapid) 3 Scores
Sedat Yilmaz1, Ismail Simsek1, Muhammet Cinar1, Hakan Erdem1, Osman Kose1, Yusuf Yazici2 and Salih Pay3, 1Division of Rheumatology, Gulhane School of Medicine, Ankara, Turkey, 2Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY, 3GATA, Ankara, Turkey
The Impact of Positive Pathergy Test on the Performance of Diagnostic Criteria in Behcet’s Disease
Fereydoun Davatchi, Bahar Sadeghi Abdollahi, Cheyda Chams-Davatchi, Farhad Shahram, Zahra Ghodsi, Tahereh Faezi, Abdolhadi Nadji, Massoomeh Akhlaghi and Roghieh Larimi, Shariati Hospital-Tehran Univ, Tehran, Iran
A Mucocutaneous Activity Index for Behcet's Disease
Gonca Mumcu1, Nevsun Inanc2, Haner Direskeneli2 and Tülin Ergun3, 1Marmara University,Faculty of Health Sciences, Department of Health Informatics and Technologies, Istanbul, Turkey, 2Marmara University School of Medicine, Istanbul, Turkey, 3Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey
Gender-Specific Differences in Adamantiades-Behçet’s Disease Presentation and Their Relationship with HLA-B5: An Analysis of 731 Subjects From the German Registry for Adamantiades-Behçet’s Disease
Nikolaos G. Bonitsis1, Liem Binh Luong Nguyen2, Nestor Papoutsis1, Andreas Altenburg1, Ina Kötter3, Alfred Mahr2 and Christos C. Zouboulis1, 1Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany, 2Department of Internal Medicine, Hospital Saint-Louis, Paris, France, 3Department of Internal Medicine II, Rheumatology Division, University Hospital Tübingen, Tübingen, Germany
Exploration of Male Gender in Heterogeneity of Association Between HLA-B51/B5 and Behçet’s Disease Using Mixture Models
Michael P. LaValley1, Hailong Cheng2, Mathilde de Menthon3 and Alfred Mahr3, 1Boston University School of Public Health, Boston, MA, 2Sunovion Pharmaceuticals Inc., Marlborough, MA, 3Hospital Saint-Louis, Paris, France
CC Chemokine RECEPTOR 5 POLYMORPHISM  In BEHÇET’S DISEASE
Fabiola Atzeni1, Luigi Boiardi2, Bruno Casali3, Enrico Farnetti3, Piercarlo Sarzi-Puttini1, Nicolo Pipitone2, Ignazio Olivieri4, Fabrizio Cantini5, Fabrizio Salvi6, Renato La Corte7, Giovanni Triolo8, Davide Filippini9, Giuseppe Paolazzi10 and Carlo Salvarani2, 1Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, 2Arcispedale S Maria Nuova, Reggio Emilia, Italy, 3Molecular Biology Laboratory, Arcispedale S. Maria Nuova,, Reggio Emilia, Italy, 4Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy, 5Stabilimento Ospedaliero Misericordia, Prato, Italy, 6Dept. of Neurological Sciences, Ospedale Bellaria,, Bologna, Italy, 7Chair of Rheumatology, University of Ferrara,, Ferrara, Italy, 8Rheumatology Unit, University of Palermo, Palermo, Italy, 9Rheumatology Unit, Ospedale Niguarda,, Milan, Italy, 10Ospedale Santa Chiara, Trento
Genome-Wide Expression Profiling of CD14+ Monocytes in Behcet’s Disease: An Upregulated TGF-b Signaling and N-Methyltransferase Activity
M. Dozmorov1, F. Ozdemir2, V. Yilmaz3, E. Eksioglu-Demiralp2, J. Wren1, G. Saruhan-Direskeneli3, A. Sawalha1 and H. Direskeneli4, 1Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Marmara University, School of Medicine, Department of Immunology, Istanbul, Turkey, 3Istanbul University, Istanbul Faculty of Medicine, Department of Physiology, Istanbul, Turkey, 4Marmara University, School of Medicine, Department of Rheumatology, Istanbul, Turkey
Parvovirus B19 in Behçet’s Disease
Zahra Habibagahi, Mojtaba Habibagahi and Said Mostafa Said Mardani, Shiraz University of Medical Sciences, Shiraz, Iran
Management and Prognosis of Non- Pulmonary Large Arterial Disease in Behcet’s Syndrome: A Reappraisal of 25 Patients From a Single Center
Hasan Tuzun, Emire Seyahi, Caner Arslan, Vedat Hamuryudan, Kazim Besirli and Hasan Yazici, University of Istanbul, Cerrahpasa Medical Faculty, Istanbul, Turkey
Long-Term Outcome of Arterial Lesions in Behçet’s Disease: A Series of 101 Patients
David Saadoun1, B. Asli2, Bertrand Wechsler2, Habib Houman3, Guillaume Geri2, Jean-Charles Piette2, Zahir Amoura2, Mathieu Resche Rigon1 and Patrice Cacoub2, 1Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, 2CHU Pitié-Salpêtrière, Paris, France, 3department of internal medicine hôpital la rabta Tunis Tunisie, France
Immunosuppressants Reduce Venous Thrombosis Relapses in Behçet‘s Disease
anne Claire Desbois1, Bertrand Wechsler2, Jean-Charles Piette3, Du Boutin1, Zahir Amoura4, Fabien Koskas1, Patrice Cacoub4 and David Saadoun5, 1Department of Internal Medicine and 2Laboratory I3 « Immunology, Immunopathology, Immunotherapy », UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, 2Hopital de la Pitie, Paris, France, 3Paris, 4CHU Pitié-Salpêtrière, Paris, France, 5Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France
Difference of Manifestations and Treatment Among Behcet's Syndrome Patients in the United States and Japan
Yuri Ohara1, Mitsumasa Kishimoto1, Tatsuo Kobayashi2, Christopher Swearingen3, M.T. Filopoulos4, Yasuharu Tokuda5, Hideto Oshikawa2, Kazuki Yoshida2, Masako Utsunomiya2, Makiko Kimura2, Masato Okada1, Kazuo Matsui2 and Yusuf Yazici6, 1St. Luke's International Hospital, Tokyo, Japan, 2Kameda Medical Center, Kamogawa City, Japan, 3University of Arkansas for Medical Sciences, Little Rock, AR, 4Hospital for Joint Diseases, New York, NY, 5University of Tsukuba, Ibaraki, Japan, 6Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY
Neuro-Behçet´s Disease in Brazil: Higher Incidence in Females and Atypical Manifestations. 
Livia A. Dutra1, Celio R. Gonçalves2, José L. Pedroso1, Pedro Braga-Neto1, Alberto A. Gabbai1, Orlando G. P. Barsottini1 and Alexandre W. S. de Souza1, 1Universidade Federal de São Paulo, São Paulo, Brazil, 2Universidade de São Paulo, São Paulo, Brazil
Some Manifestations Disappear Earlier Than Others in Behcet’s Syndrome
F. Sevgi Sacli1, Emire Seyahi2, Serdal Ugurlu3, Yilmaz Ozyazgan2, Cem Mat2 and Hasan Yazici2, 1Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 2University of Istanbul, Cerrahpasa Medical Faculty, Istanbul, Turkey, 3Rheumatology, Istanbul, Turkey
Spectrum of Cardiac Lesions in Behçet’s Disease
Guillaume Geri1, Bertrand Wechsler1, Du Le Thi Huong1, Richard Isnard2, Jean-Charles Piette1, Zahir Amoura1, Mathieu Resche Rigon3, Patrice Cacoub1 and David Saadoun3, 1CHU Pitié-Salpêtrière, Paris, France, 2Department of Cardiology, CHU Pitié-Salpêtrière, 47-83 Boulevard de l'hôpital, 75651 Paris Cedex 13, Paris, France, Paris, France, 3Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France
Neurological Involvement in Behcet’s Disease: A Worrying Cause of Morbidity and Mortality
Rosaria Talarico, Claudia Ferrari, Anna d'Ascanio and Stefano Bombardieri, Rheumatology Unit, Pisa, Italy
Consensus Statements for Management for Intestinal Behcet’s Disease in Japan
Mitsuhiro Takeno1, Reikou Watanabe1, Hirotoshi Kikuchi2, Masakazu Nagahori3, Kazuyoshi Saito4, Nagamu Inoue5, Michiko Kurosawa6, Yoshiaki Ishigatsubo1 and Behcet's Disease Reserch Commitee of Japan7, 1Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Teikyo University, Tokyo, Japan, 3Tokyo Medicai Dental University, Tokyo, Japan, 4University of Occupational & Environmental Health, Japan, Kitakyushu, Japan, 5Keio University, Tokyo, Japan, 6Juntendo University, Tokyo, Japan, 7Yokohama, Japan
See more of: ACR Abstract Submissions

To see other sessions for this day, use the date buttons to the left.